2016
NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States
Prasad ML, Vyas M, Horne MJ, Virk RK, Morotti R, Liu Z, Tallini G, Nikiforova MN, Christison-Lagay ER, Udelsman R, Dinauer CA, Nikiforov YE. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer 2016, 122: 1097-1107. PMID: 26784937, DOI: 10.1002/cncr.29887.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentCarcinomaCarcinoma, PapillaryChildDNA Mutational AnalysisFemaleHigh-Throughput Nucleotide SequencingHumansMaleMutationNew EnglandNuclear Pore Complex ProteinsOncogene Proteins, FusionProto-Oncogene MasProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-etsProto-Oncogene Proteins c-retReceptor, trkAReceptor, trkCRepressor ProteinsReverse Transcriptase Polymerase Chain ReactionThyroid Cancer, PapillaryThyroid Neoplasms
2003
Tumor Size and Extent of Disease at Diagnosis Predict the Response to Initial Therapy for Papillary Thyroid Carcinoma in Children and Adolescents
Powers PA, Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Francis GL. Tumor Size and Extent of Disease at Diagnosis Predict the Response to Initial Therapy for Papillary Thyroid Carcinoma in Children and Adolescents. Journal Of Pediatric Endocrinology And Metabolism 2003, 16: 693-702. PMID: 12880118, DOI: 10.1515/jpem.2003.16.5.693.Peer-Reviewed Original ResearchConceptsPapillary thyroid carcinomaExtent of diseaseLarger tumor sizeTumor sizeExtensive diseaseInitial treatmentThyroid carcinomaRadioactive iodine treatmentClass IV patientsInitial therapyFirst remissionIV patientsPersistent diseaseMultifocal diseasePatientsClass IIIRemissionClass IIIodine treatmentDiseaseClass IDiagnosisTreatmentCarcinomaChildren